Tyson Foods, Inc. · TSN · FY2026 Q4 · Calendar Q4 2026
Tyson’s FY2027 plan pairs lower sales with continued operating investment
Tyson’s FY2027 outlook rests on holding profitability through cost discipline and network optimization as sales are expected to decline. Management’s investment in branded products, automation and beef capacity supports that plan, while commodity costs and execution remain important tests.
Research this report with FN2. Free to start; review your question before sending.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about TSN FY2026 Q4
Choose a question to continue your researchFree to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
Transcript intelligence
What changed
Management introduced FY2027 guidance for a 3.5%–5.5% sales decline and $1.7B–$2.15B of operating income, alongside a higher $1.1B–$1.4B capex plan. The call also highlighted a new Allied Beef supply partnership and a planned second-shift reopening at Amarillo by summer 2027.
Guidance delta
FY2027 outlook: sales down 3.5%–5.5%; operating income of $1.7B–$2.15B. Planned capex is $1.1B–$1.4B, with Chicken and Prepared Foods prioritized. The supplied analysis characterizes guidance sentiment as lowered; it does not specify a prior FY2027 range for comparison.
Key takeaways
- FY2026 adjusted operating income was $1.98B and EPS was $3.44, according to the supplied call analysis.
- Prepared Foods had marginal revenue growth and improved margin, but shelf-space gaps remain.
- Management expects FY2027 sales to decline, while targeting $1.7B–$2.15B operating income.
- A new Allied Beef partnership and the planned Amarillo second-shift reopening are intended to support beef supply and plant utilization.
- Management cited early repeat demand for the Jimmy Dean high-protein platform and Tyson Chicken Cups; the supplied analysis reports sales of $38M and $28M, respectively.
Management priorities
- Focus on consumer-preferred brands, premium and value-added products, and high-protein launches.
- Improve best-cost execution through network optimization, automation, AI and robotics.
- Prioritize capex in Chicken and Prepared Foods and deepen joint business planning with top customers.
- Develop cattle supply and beef-plant utilization, including the Allied Beef partnership and planned Amarillo shift reopening.
Follow TSN with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Piper Sandler | Overweight | Overweight | Maintain | Oct 7, 2026 |
| JP Morgan | Overweight | Neutral | Upgrade | Sep 18, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | Sep 4, 2026 |
| Barclays | Overweight | Overweight | Maintain | Sep 4, 2026 |
| Bernstein | Market Perform | Market Perform | Maintain | Jul 2, 2026 |
| B of A Securities | Neutral | Neutral | Maintain | Jul 2, 2026 |
| Stephens & Co. | Equal Weight | Equal Weight | Maintain | May 5, 2026 |
| Mizuho | Outperform | Buy | Maintain | Mar 26, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Apr 15, 2025 |
| HSBC | Reduce | Reduce | Maintain | May 7, 2024 |
| Goldman Sachs | Neutral | Neutral | Maintain | Apr 17, 2024 |
| Credit Suisse | Neutral | Neutral | Maintain | Feb 7, 2023 |
| Argus Research | Hold | Buy | Downgrade | Sep 13, 2022 |
| Buckingham Research | Neutral | Neutral | Maintain | Feb 20, 2020 |
| Buckingham | Neutral | Neutral | Maintain | Feb 20, 2020 |
| Bank of America | Buy | Buy | Maintain | Nov 13, 2019 |
| Argus | Buy | Hold | Upgrade | May 14, 2019 |
| Vertical Research | Buy | Hold | Upgrade | Jan 10, 2019 |
| Vertical Group | Buy | Hold | Upgrade | Jan 10, 2019 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | May 8, 2018 |
| Pivotal Research | Hold | Sell | Upgrade | Nov 13, 2017 |
| Jefferies | Buy | Buy | Maintain | Oct 30, 2017 |
| CLSA | Buy | Outperform | Maintain | Oct 10, 2016 |
| BB&T Capital | Hold | Buy | Downgrade | Mar 4, 2016 |
| RBC Capital | Sector Perform | Outperform | Downgrade | Jan 5, 2016 |
| Cleveland Research | Buy | Neutral | Upgrade | Feb 5, 2015 |
| Keybanc | Buy | Buy | Maintain | Jul 29, 2014 |
| DA Davidson | Buy | Buy | Maintain | Jul 10, 2013 |
| Miller Tabak | Buy | Neutral | Upgrade | May 7, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $65.12. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Bernstein | Alexia Howard | $72 | $63.21 | +10.6% | Nov 17, 2026 |
| Piper Sandler | Michael Lavery | $72 | $63.94 | +10.6% | Nov 17, 2026 |
| J.P. Morgan | Thomas Palmer | $65 | $63.95 | -0.2% | Nov 17, 2026 |
| Piper Sandler | Analyst unavailable | $56 | $51.97 | -14.0% | Oct 7, 2026 |
| Piper Sandler | Analyst unavailable | $66 | $51.74 | +1.4% | Sep 10, 2026 |
| Barclays | Analyst unavailable | $75 | $51.76 | +15.2% | Sep 4, 2026 |
| BMO Capital | Andrew Strelzik | $65 | $51.76 | -0.2% | Sep 4, 2026 |
| Bernstein | Alexia Howard | $66 | $58.12 | +1.4% | Aug 4, 2026 |
| Coker Palmer | Thomas Palmer | $65 | $57.48 | -0.2% | Jul 14, 2026 |
| Bernstein | Analyst unavailable | $63 | $58.43 | -3.3% | Jul 2, 2026 |
| Piper Sandler | Michael Lavery | $78 | $56.2 | +19.8% | Jun 18, 2026 |
| Piper Sandler | Analyst unavailable | $80 | $68.76 | +22.9% | May 4, 2026 |
| Bernstein | Analyst unavailable | $69 | $65.74 | +6.0% | Feb 3, 2026 |
| BMO Capital | Andrew Strelzik | $73 | $65.74 | +12.1% | Feb 3, 2026 |
| Barclays | Analyst unavailable | $78 | $65.74 | +19.8% | Feb 3, 2026 |
| BMO Capital | Analyst unavailable | $67 | $56.2 | +2.9% | Jan 8, 2026 |
| Piper Sandler | Michael Lavery | $61 | $59.56 | -6.3% | Dec 12, 2025 |
| Stephens | Pooran Sharma | $61 | $55.75 | -6.3% | May 6, 2025 |
| Coker Palmer | Thomas Palmer | $60 | $60.54 | -7.9% | Apr 15, 2025 |
| Piper Sandler | Michael Lavery | $58 | $61.69 | -10.9% | Nov 13, 2024 |
| BMO Capital | Andrew Strelzik | $62 | $61.69 | -4.8% | Nov 13, 2024 |
| Barclays | Benjamin Theuer | $76 | $62.66 | +16.7% | Nov 12, 2024 |
| Bank of America Securities | Peter Galbo | $62 | $59.85 | -4.8% | Oct 15, 2024 |
| Piper Sandler | Michael Lavery | $50 | $60.52 | -23.2% | Sep 25, 2024 |
| Barclays | Benjamin Theuer | $72 | $65.13 | +10.6% | Sep 5, 2024 |
| BMO Capital | Andrew Strelzik | $60 | $62.08 | -7.9% | Aug 6, 2024 |
| Coker Palmer | Thomas Palmer | $63 | $62.51 | -3.3% | Aug 5, 2024 |
| Piper Sandler | Michael Lavery | $57 | $58.33 | -12.5% | May 7, 2024 |
| BMO Capital | Andrew Strelzik | $58 | $58.28 | -10.9% | May 7, 2024 |
| Barclays | Benjamin Theuer | $69 | $58.12 | +6.0% | Apr 16, 2024 |
| Coker Palmer | Thomas Palmer | $62 | $57.6 | -4.8% | Apr 3, 2024 |
| Loop Capital Markets | Andrew Strelzik | $46 | $47.77 | -29.4% | Nov 14, 2023 |
| Stephens | Ben Bienvenu | $70 | $47.58 | +7.5% | Nov 14, 2023 |
| J.P. Morgan | Kenneth Goldman | $55 | $46.39 | -15.5% | Nov 10, 2023 |
| UBS | Kevin Caliendo | $37 | $52.66 | -43.2% | Jul 24, 2023 |
| Deutsche Bank | Steve Powers | $35 | $50.39 | -46.3% | May 19, 2023 |
| Bernstein | Alexia Howard | $48 | $48.95 | -26.3% | May 9, 2023 |
| J.P. Morgan | Analyst unavailable | $63 | $59.92 | -3.3% | Feb 7, 2023 |
| Credit Suisse | Analyst unavailable | $58 | $61.08 | -10.9% | Feb 7, 2023 |
| Goldman Sachs | Analyst unavailable | $66 | $61.08 | +1.4% | Feb 7, 2023 |
| Piper Sandler | Analyst unavailable | $65 | $65.75 | -0.2% | Feb 1, 2023 |
| Barclays | Analyst unavailable | $58 | $67.33 | -10.9% | Nov 28, 2022 |
| J.P. Morgan | Analyst unavailable | $70 | $64.34 | +7.5% | Nov 15, 2022 |
| BMO Capital | Analyst unavailable | $75 | $64.83 | +15.2% | Nov 15, 2022 |
| Piper Sandler | Michael Lavery | $79 | $79.92 | +21.3% | Aug 9, 2022 |
| Piper Sandler | Michael Lavery | $85 | $92.84 | +30.5% | May 10, 2022 |
| Piper Sandler | Michael Lavery | $81 | $90.1 | +24.4% | May 3, 2022 |
| BMO Capital | Kenneth Zaslow | $99 | $87.14 | +52.0% | Mar 18, 2022 |
Track every rating change on TSN the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationTyson Foods, Inc. operates as a prominent global food producer, encompassing a broad range of activities across four core divisions: Beef, Pork, Chicken, and Prepared Foods. Within its Beef and Pork segments, the company manages the entire process from live cattle and hogs to their transformation into various meat products. This includes fabricating whole carcasses into primary and secondary cuts, providing case-ready options, and producing fully cooked meats. Its Chicken division is responsible for raising and processing poultry, delivering a spectrum of fresh, frozen, and value-added chicken items, and also supplying breeding stock. Additionally, Tyson markets specialty by-products such as animal hides. The Prepared Foods unit focuses on manufacturing and distributing a diverse portfolio of frozen and refrigerated convenience foods.…
Historical context
All TSN earningsConsumer Defensive peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| BJ BJ's Wholesale Club Holdings, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | -2.0% | BJ’s Q3 guidance rises, but one-time benefit clouds run rate |
| WMT Walmart Inc. | FY2027 Q3 · Calendar Q4 2026 | +1.9% | -1.0% | Walmart raises FY2027 outlook as e-commerce, ads and membership grow |
| TGT Target Corporation | FY2026 Q3 · Calendar Q4 2026 | +29.3% | +4.0% | Target’s Q3 rebound lifts outlook, while home and apparel remain weak spots |
Latest beats and misses
Who reports nextBeat on EPS
- INTUFY2027 Q1 · November 19, 2026+18.3% EPS-6.2% move
- ROSTFY2026 Q3 · November 19, 2026+2.1% EPS-2.8% move
- ESTCFY2027 Q2 · November 19, 2026+16.2% EPS+2.0% move
- KEYSFY2026 Q4 · November 19, 2026+7.1% EPS-1.5% move
- WSMFY2026 Q3 · November 19, 20260.0% EPS-15.2% move
- WMGFY2026 Q4 · November 19, 2026+50.9% EPS-0.6% move
Missed on EPS
- NTESFY2026 Q3 · November 19, 2026-12.8% EPS-11.4% move
- FUTUFY2026 Q3 · November 19, 2026-7.8% EPS+4.8% move
- BABAFY2027 Q2 · November 19, 2026-29.2% EPS-1.3% move
- SQMFY2026 Q3 · November 17, 2026-3.0% EPS-5.5% move
- VIKFY2026 Q3 · November 17, 2026-12.6% EPS+4.4% move
- XPFY2026 Q3 · November 16, 2026-3.0% EPS-2.5% move
Get the TSN recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-16T19:15:42.731756+00:00
- FN2 earnings calendar · 2026-11-17T01:23:14.281446+00:00
- Polygon adjusted daily market bars · 2026-11-17T07:40:45.026254+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-17T07:40:45.023037+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-17. For educational purposes only; not investment advice.